• 13000+Virtual Attendees
  • 150+Speakers
  • 70+Virtual Sessions
  • 5+Days of Content

Day 1 (CET)


Becoming a medicines company powered by data and digital

Bertrand Bodson Chief Digital Officer, Member of the Executive Board Novartis


Engaging customers during global disruption

  • Learn about the trending digital continuity strategies and how the industry is rapidly adapting to COVID-19.

Marc Valdiviezo VP Strategy and Applied Digital Transformation Indegene

Michelle Keefe President Commercial Solutions Syneos Health

Elena Bonfiglioli Health and Life Sciences EMEA Microsoft


The Health Start-Up Challenge Final

  • Our 6 startup finalists each have just three minutes to demonstrate disruption and win your support to win the crown as 2020 Health Start-Up of the Year

Claus Møldrup Chief Executive Officer Drugstars

Robert Chu CEO embleema

Joachim Werr CEO Health Navigator

Olli Rundgren Chief Executive Officer Psyon Games

Chris Robson Chief Executive Officer Living With

Yossi Bahagon Co-founder Sweetch


Reuters News Interview: Coronavirus – what lies ahead for the global community?

Axel Threlfall Editor-at-Large Reuters

David Heymann Professor of Infectious Disease Epidemiology The London School of Hygiene & Tropical Medicine


How pharma can find wins through start-up collaboration post Covid-19

Jessica Federer Ex-CDO Bayer


Case Study: Almirall’s Digital Garden that partners with start-ups to innovate together

  • Provide start-ups with the nutrients they need to grow into the next digital disruptor
  • Co-create cutting edge digital solutions when you provide pioneering start-ups leveraging pharma expertise
  • Learn how you can streamline your own operations through symbiotic sharing of information and processes

Mohanad Fors Head, Global Commercial Digital Innovation & Head Botanist, Digital Garden Almirall

Mercedes Diz Head of Global Marketing, Market Access & KOL Management Almirall


How blockchain technology could reinvent the pharmaceutical supply chain

  • Hear the latest on the Innovative Medicines Initiative Programme “Blockchain Enabled Healthcare”, a consortium approach to establish the use of blockchain in the healthcare industry
  • Find out why Novartis see blockchain technologies having the potential to hugely improve third party risk management
  • Learn how agreed and standardised digital identifiers can reduce admin and streamline processes across the entire supply chain

Marco Cuomo Manager, Applied Technology Innovation Novartis

Daniel Fritz Domain Architect Supply Chain & External Supply Novartis


Inside out innovation: How Ferring is creating the next generation of business models and solutions by pioneering with an eco-system of innovative start-ups & tech players

  • Understand how your company can leapfrog into disruptive business models
  • To succeed, you must first fail: grasp how commercial innovation and positive failure are intrinsically linked
  • Explore how to structure the organisation to develop commercial agility

Haider Alleg Global Head of Digital Excellence Ferring


Moving from digital to digital health in order to sustain pharma

Myles Furnace Digital Health and Data Lead UK Ipsen


Panel: Where is tech innovation bringing real value in healthcare – and how are pharma companies keeping pace?

  • In which areas are new tech advances driving innovation in healthcare? How do pharma companies need to adapt to stay relevant?
  • Discover how strong data analysis is now seen as a core competency and where it can reveal unseen insights to add significant business value
  • Learn how integrating AI, blockchain, VR/AR and other emerging technologies is accelerating productivity and efficiencies across the industry
  • Understand how working with startups can accelerate digital innovation and foster new ways of working for better overall outcomes

Ali Abusnina Senior Data Scientist Boehringer Ingelheim BI X Digital Lab

Haider Alleg Global Head of Digital Excellence Ferring

Amy Peck Founder & CEO EndeavorVR


Clinical innovation organisation for a post Covid-19 world

Andreas Koester Former VP, Clinical innovation Janssen


Panel: IMI Trials@Home: Reshaping Remote Decentralised Clinical Trials in Europe

  • How to analyse previous centralised/RDC/hybrid trials and develop best-practice protocols to enable a pan-EU pilot
  • Ensure smart, complaint roll-out of RDCT’s by forging strong partnerships with HCPs, participants, regulators and other relevant stakeholders
  • Scanning, characterizing available technologies to support RDCTs and applying design thinking processes to create a robust, end-to-end technology package

Diederick E. Grobbee Professor of Clinical Epidemiology UMC Utrecht

Shelly Barnes Global Clinical Innovations UCB

Christian Born Djurhuus VP, Head of Digital Transformation, Global Innovation Novo Nordisk


LEO Innovation Lab: how a new clinical paradigm was created within a 110-year old company

  • How an open-minded approach to evidence enabled the identification of new subtypes of diseases through RWD
  • A guide to successful remote clinical trials in dermatology and how this was done in an Innovation Lab, separate to the mothership
  • Simplicity is key: avoid complexity on the most complex treatments and ensure your trials don’t add to the EHR burden through careful management

Rasmus Hogreffe Head of Virtual Clinical Trials LEO Innovation Lab


Decentralized trials radically accelerate and power advances in patient centric approach

  • Review two recent case studies highlighting how decentralized trials throughout the trial process can positively impact trial success.
  • In a Macular Degeneration study, digital technology was leveraged to remotely screen 11,000 patients and decrease the screening and enrollment timelines by 50%.

Alison Holland Head of Virtual Clinical Trials Medable


The Clinical Entrepreneur: how agility will be a necessity for successful digitization of the trial

  • Examples of Lundbeck’s efforts to rewrite clinical planning & execution through a faster, iterative, learning model
  • Man vs machine – understand how to balance resources in a smarter way
  • A fresh perspective on the steps required to get your trial from idea to infinity

Mads Dalsgaard Senior Vice President, Head of Experimental Medicine & Clinical Development Lundbeck


Data interoperabilitiy and their insights

Renaud Sermondade VP, Global Head of Insights and Analytics Sanofi


Panel: From ‘go digital’ to ‘go create a new model’: the expanded scope for the Chief Digital Officer

  • How an integration of digital techniques with chemistry and biology, especially in R&D, can enable smarter decision making and de-risking across the organisation
  • Hear how Cellarity (part of Flagship Pioneering) is reversing diseases across patient types, tissue types and molecular variances across organs.
  • Learn about Sumitomo Dainippon Pharma/Roivant approach to running things in parallel rather than series, automating operations finding new incentive models and other initiatives to get drugs to patients faster

Dan Rothman Chief Digital Officer Sumitomo Dainippon Pharma

Milind Kamkolkar Chief Digital Officer Cellarity

Paul Simms Chairman eyeforpharma by Reuters Events

Day 2 (CET)


Deliver a personalised customer experience through marketing automation

  • Use marketing automation to create memorable customer journeys through the most relevant channels
  • Further improve CX by gathering and analysing data seamlessly through an integrated platform

Christian Scheuer VP, Global Commercial Affairs & Excellence LEO Pharma


Guarantee launch excellence – adopt new technologies driving scientific engagement to the next level

  • Align key stakeholders behind your launch during emergency situations through technology that enhances cross-market interactive professional networking
  • Enhance your value proposition by creating scalable scientific engagement across the globe with KOLs
  • Deliver advanced analytics across pre and post launch communities through world-class customer data management integration

Peter Velev Founder Credoweb


Adopt targeted chatbot placement to more efficiently create one-to-one interactions under budgetary constraints

  • Determine whether you can minimise expenditure by replacing or avoiding human support for non-promoted brands.
  • Best practice in rapidly providing a large pool of medical information to HCPs, patients and carers.
  • Generate new insights into customer behaviours by integrating user interactions into data collection strategy.

Kym Jacks-Bryant Head, Digital Centre of Excellence Norgine


Reuters News Interview: In coversation with Paul Stoffels, Chief Scientific Officer, Johnson & Johnson

After the breaking news that Johnson & Johnson has a lead vaccine candidate for Covid-19 and commits to supplying 1 billion vaccine doses worldwide for emergency pandemic use, Axel Threlfall, Editor-At-Larger of Reuters interviews Paul Stoffels, Chief Scientific Officer at Johnson & Johnson. They dive further into that announcement and how pharma can collaborate further in the current pandemic.

Axel Threlfall Editor-at-Large Reuters

Paul Stoffels Chief Scientific Officer Johnson & Johnson


Panel: What culture and capability changes are required to accelerate digital adoption throughout your organisation

  • Encourage greater digital implementation amongst laggard teams by using metrics and KPIs that more tangibly demonstrate long-term impact
  • Create a global strategy that evolves to meet local affiliate constraints and specific customer requirements, whilst reducing duplication of effort

Florent Edouard SVP, Global Head of Commercial Excellence & Customer Engagement Grünenthal

Abel Archundia SVP, Global Head of IT & Digital Transformation Bayer

Philippe Kirby Director, Digital Capabilities & Analytics Lead MSD

Todd Neuville Worldwide Leader, Life Sciences Amazon Web Services


Case Study: Beyond the medicine: Co-creating solutions that meet real world patient and HCP needs

  • Explore 3 projects from Roche Innovation Lab and hear about the journey behind each project from first interaction to final solutions
  • Understand how each solution deliver value to the users by getting insights in user feedback and Roche’s learnings

Jonas Kierkegaard Head of Innovation Lab Roche


Case Study: driving innovation through next generation CRM

  • Learn how Alimera was able to quickly migrate from a closed solution to harness the power of the Salesforce platform enabled by CT Mobile
  • Understand how this change has improved self-sufficiency and set the stage to enable advanced, and a more agile response to future initiatives such as a COVID-19 response plan with remote- and self-detailing

Kotaro Sai CRM Owner Alimera Sciences

Denny Gracey VP Business Development Customertimes


Case Study: achieve commercial excellence with a patient-centric framework to pioneer patient access

  • Streamline your commercial strategy by holistically assessing and addressing unmet customer needs
  • Boost efficiency with Sandoz’s framework introducing integrated marketing and sales agenda

Alexey Cherchago Head of Sales Excellence Europe Sandoz


Challenge the ‘old pharma’ mindset with evidence-based outcomes

  • Empower the patients voice in-house and convince all functions of its value by developing measurable insights
  • Break down silos to swiftly incorporate the patient’s perspective when developing new services

Geoff Rollason Patient Experience & Service Director - Oncology Pfizer


Bring your Patient Support Program out of the dark

  • Hear how a real life Patient Support Program was turbocharged by linking actual patient medicine usage, in real-time, to the PSP’s dashboard
  • Phillips-Medisize, as one of the few companies to have made this connection in a marketed drug product, will share our experiences of building and running such a system – from drug to data
  • Linking medicine usage, in real-time, to PSP’s not only provides the light needed to focus PSP activities, but also helps sales and marketing teams monitor, and respond to, medicine usage patterns including compliance and persistence

Kevin Deane VP and Head of Digital Health Phillips-Medisize, a Molex Company


Targeting patient engagement across the lifecycle

  • Building on executive buy-in to enable an all-inclusive, company-wide approach to patient engagement – a must in the rare disease sector
  • Why an online resource for employees across functions and geographies can help facilitate and support patient engagement
  • A case study and techniques for transferring and translating knowledge between disease areas and between physicians of a successful approach between disease areas

María José Sanchez-Losada General Manager, Spain and Portugal CSL Behring


How pharma must collaborate and cooperate from a Cancer NGO perspective

Cary Adams CEO Union for International Cancer Control


Panel: We all have a shared interest; better healthcare for patients

  • From small through to global organisations; discover what is best practice for engaging patient groups with various capabilities
  • You’re on the frontline, so lead from the front; why those in patient-centric roles must be the patients champion internally
  • The future is now: Understand how to pave the way for a new era of collaboration

Paul Robinson European Lead, Patient Innovation MSD

Olive Fulton Patient & Public Involvement Lead Asthma UK Centre for Applied Research

Vanessa Pott Director, Patient Advocacy & Strategic Partnerships Merck

Isabelle Bocher-Pianka Chief Patient Affairs Officer Ipsen

Paul Simms Chairman eyeforpharma by Reuters Events


Driving value – the evolving strategic role of Medical Affairs

  • Connect science, clinical outcomes and patient value to build a future-fit Medical Affairs function
  • Build a positive reputation and drive scientific exchange with an ever-expanding external stakeholder community
  • Identify, optimize and integrate external insights to inform medical/corporate strategy and enhance value delivery
  • Deliver strategic impact for the C-Suite as a business savvy and agile partner

Charlotte Kremer EVP, Head of Medical Affairs Astellas


Future-proof medical affairs: how to evolve into an agile, customer-driven function

  • Medical Governance frameworks to structure around the customer, internal and external, to co-create and present value
  • Excel in an algorithm and data driven healthcare decision-making system

Michael Zaiac Head of Medical Affairs, Oncology, Europe Novartis


Empower your medical field force and fulfil stakeholder need

  • Don’t limit your MSLs to HCPs: define their new role on the frontline of pharma’s field force expanding across patient groups and market access authorities
  • MSLs aren’t superhuman: help them realise their full potential with a clear overall field-team strategy, whilst building capabilities in key business operational and soft skills
  • MSLs aren’t superhuman: help them realise their full potential with a clear overall field-team strategy, whilst building capabilities in key business operational and soft skills

Emma Booth Director, Head of Medical Strategy and Operations Amgen


How LEO has incubated impactful solutions for a digital world

John Zibert Chief Medical Officer LEO Innovation Lab


Panel: Conduct your evidence symphony - a new paradigm to align cross-company evidence generation around outcomes

  • Better identify study gaps and requirements with Medical becoming the transceiver of scientific information across RWE studies and clinical trials
  • Why every company should centralise company evidence generation strategy to be led by Medical Affairs

Niko Andre Head of Global Medical Affairs Roche

Klaus Dugi EVP, Chief Medical Officer Ferring

Michael Seewald VP, Global Evidence, Medical AstraZeneca

Pol Vandenbroucke SVP, Chief Medical Officer, Hospital Business Unit Pfizer

Michael Axelson Head of Clinical Research Tempus

Charlotte Kremer EVP, Head of Medical Affairs Astellas

Day 3 (CET)


Enlighten medical decision-making with an integrated insights system

  • How to ensure real time insight is at the heart of your strategic decisions
  • Locate the insight source and turn insights into action for short and long term value to the business, HCP and patient
  • Ensure systems are purpose led, not technology – choosing the right system your needs

Victoria Ho Director, MSL Excellence EU/RoW Jazz Pharmacauticals


Panel: Drive medical excellence with novel digital application

  • Maximise limited physician interaction time with data informed field force decision-making and content generation
  • Advice on your digital advisory boards: Lessons learnt from GSK on creating strong engagement and stakeholder experience
  • Provide medical education through virtual channels to increase efficiencies and reduce customer burden

Mark Johnson Director of Digital Engagements, Medical GSK

Eddie Guzdar Medical Head of Neurology & Immunology (Rheumatology) Sanofi


Beyond digital: making marketing meaningful

Paul Dixey Multichannel Lead, UK Novartis


Unlock the power of social media as a reactive and direct engagement channel

Cyril Mandry Senior Director, Marketing MSD


How to bring meaningful and measurable value to social in Pharma – before it’s too late

Manu Field Social Media Strategy Leader Roche


An open minded approach to commercial success

Manuel Reiberg Managing Director, UK Daiichi Sankyo


Panel: Create a holistic customer experience: break down silos to harness the combined power of commercial capabilities and medical authenticity

  • See the whole customer journey by aligning commercial and medical teams under one overarching engagement strategy, across all field and digital initiatives
  • Why education principles and disease led strategy are crucial to successful collaboration
  • Redefine “a good customer relationship” by leveraging combined insights and capabilities without tarnishing the valued authenticity of an independent medical affairs

Heather Moses Global Marketing Leader & Head of Medical Affairs Roche

Sandra Silvestri SVP, Global Head of Medical, China & Emerging Market Business Unit Sanofi

Ana Kostova AVP, Country Manager Germany Allergan

Philippe Kirby Director, Digital Capabilities & Analytics Lead MSD


Future therapy: the Novartis roadmap for Digital Therapeutics

  • See how Novartis is building digital therapies into its portfolio and the interplay with traditional therapies
  • How regulators and pharma need to evolve in cooperation for the benefit of patients

Jeremy Sohn VP, Global Head of Digital BD&L Novartis


Amplify prescription opportunities for digital therapeutics through deeper insights into physician perspectives

  • Explore how Kaia Health are maneuvering health systems in USA and EU to increase uptake amongst payers and providers

Jonas Duss US CEO, Co-Founder Kaia Health


Activating the Ecosystem around DTx: a vital activity for enabling adoption

  • Why education and awareness are critical for every DTx initiative - the last mile
  • Importance of demonstrating the health economics of DTx - country stakeholder groups are champions
  • Proposing the investigation of a Joint European Assessment Framework for DTx

Jessica Shull European Lead Digital Therapeutics Alliance


How commercial leaders can make precision medicine a reality

Richard Barker Co-Founder and CEO New Medicine Partners


Superior user experience drives outcomes, retentiona & rich data

Olivier Jarry President & Chief Commercial Officer DarioHealth


Standalone or integrated? Determine whether DTx should be a separate business unit within your company

Stephen Dunne Chief Digital Therapeutics Officer Alpha

Francesca Wuttke Chief Digital Officer Almirall


Smart digital leadership and learning from China's Covid-19 management


Panel: Work with the patient as a partner to co-create and co-evolve digital therapies

  • Establish a patient-first mindset and understand the best ways to facilitate patient involvement in your development
  • Incorporate the science of behaviour change to provide greater traction and outcomes for patients
  • Explore ways to raise digital adherence and better patient outcomes

David Verdura Chief Operating Officer Curelator

Door Vonk Founder Tired of Cancer

Olivier Jarry President & Chief Commercial Officer DarioHealth

Delora Denney Patient & Clinical Support Advisor Curelator

Megan Coder Executive Director Digital Therapeutics Alliance


What the JLabs can teach us about innovating together

Melinda Richter Global Head, JLabs Johnson & Johnson


Partnership in practice: Happify and Sanofi’s new platform for patient engagement and quality of life

  • Why addressing key co-morbidities for individuals living with multiple sclerosis (MS), including depression and anxiety, digitally, opens new doors
  • Understand the key synergies such as relationships with large US health plans and employers
  • How the partnership conducted a global pilot study across 50 countries through social media, leveraging their existing consumer digital therapeutic platform

Chris Wasden Head of HappifyDTx Happify Health


New standards of care that enable pharma companies to commercialize digital health solutions and allow HCPs to offer more

  • Examine differentiated business models and best practice for forward-thinking pharmaceutical companies
  • A guide to solution-oriented commercialization models that encourage internal and external stakeholders to drive uptake
  • How the magic formula [Science + Data + Technology + Evidence = patient-centric medicine] works in DTx

Anish Shindore Head of Digital Acceleration - DTx Sanofi

Day 4 (CET)


Patient-centric trials are digital trials

  • Use technology to create patient-preferred trials – the trials patients would choose. Integrate new processes to modernise the delivery of development
  • Raise your status with patient community with more ambitious endpoints, aligned goals and a new Standard of Care

Sebastian Stratmann Senior Manager, Clinical Innovation Merck


End to end clinical trials using patient records: run randomised trials entirely based on real world data

  • Hear how the CPRD are combing PRO & EHR to assess clinical effectiveness purely from RWD sets

Tim Williams Head of Research CPRD


Merging man and machine: Unleash the potential of data to empower patients

  • Recruit patient cohorts with easily accessible technology and meet them in the most convenient place possible – their home
  • Improve both quality and breadth of data generated through PROs by exploiting trending wearable technology

Celine Ulmann Head of Digital Innovation R&D Almirall


The future is collaborative: How open innovation can enable patient-centric research

  • Understand how trust, mutual benefits and transparency can truly change the collaboration model
  • Explore how to engage a network of scientifically minded patients who can drive a new era of open innovation in R&D
  • Deliver patient relevant solutions by bridging the language gap between insights and research activities

Niclas Nilsson Head of R&D Open Innovation LEO Pharma


How AI helps lab technicians automate the counting of Colony Forming Units

  • Hear how Radix has worked with GSK to develop a web-based AI application to assist lab technicians with the counting and verification of bacterial colonies
  • See how a Machine Learning model automates the detection of virulent and avirulent colonies and what level of accuracy can be achieved fully automatically
  • Learn how lab technicians were involved from the start and got access to a working application after just one sprint to maximise the value delivered to the end-user

Laurent Sorber CTO Radix


Engage patients to shape your clinical research

  • Why treating patients as experts in their own condition leads to better trial recruitment and retention

Gareth Powell Business Development Officer National Institute for Health Research


A perspective on pharma innovation from teen cancer groups

Simon Davies CEO Teen Cancer America


Panel: No trust, No Data – Education and collaboration

  • Case Study: How the new #DataSavesLives EPF initiative is improving patient perspectives on data use by providing complex information in an understandable and accessible way
  • Understand the importance of trust in improving data sharing attitudes as patient ownership increases

Nicola Bedlington Special Advisor European Patients Forum

Brendan Barnes Director IP & Data Protection EFPIA

Michael Strübin Director, Digital Health MedTech Europe

Richard Stephens Patient Advocate NCRI

Paul Simms Chairman eyeforpharma by Reuters Events


Case Study: Bridging the divide between US and EU common data models

  • How the CPRD are translating UK patient records into the FDAs Sentinel Programme and IMI EHDEN’s common data models to extend pharmacovigilance across continents

Puja Myles Head of Observational Research CPRD


Case Study: Novartis’ AE Brain - AI that predicts adverse events and product complaints from your digital channels

  • Use AI to identify potential safety cases and product technical complaints across your complete digital channel spectrum, including chatbots, CRM notes, social media, apps and email. And its GxP too
  • Scale Xperience: A novel solution to scaling in a global enterprise solving compliance barriers, organisational silos, avoiding AI bias, adoption hurdles and sustainable funding

Abhimanyu Verma Lead, Applied Technology Innovation Novartis


How to win friends and influence trial design

Alonso Fernandez Head of Evidence and Value Generation Takeda


Case study: Achieve RWE-only regulatory label expansion

  • Why an RWE-only submission strategy meant lower costs and overall faster approval process in comparison to the traditional study process
  • Agree on study design and methodology with early regulatory engagement
  • How to ensure regulatory-standard RWD - the steps taken to ensure data sources were appropriate and of high quality, ensuring credibility

Chris Boone VP, Global Medical Epidemiology & Big Data Analysis Pfizer


The 4th Generation – where RWD, AI and the Cloud bring RWE to the Enterprise

  • Understand why challenges persistent in gaining real, actionable insights from patient data without expensive, time consuming curation and inaccurate proxies
  • Gain large-scale insights by moving away from specialised, contracted datasets by using AI to merge and structure data
  • Gain insights on large-scale structured data through 4th Generation RWE for the enterprise, which combines on-demand, deeply curated data with advanced AI tools
  • How advanced AI methodologies are being used to find patterns beyond published literature and past research reports.

Jeff Elton CEO Concerto HealthAI


Case study: Aligning regulatory and HTA decision-making around RWE assessment - CAT Initiative

  • Overview of the barriers and limitation to uptake of RWE in regulatory and HTA decision-making in Canada
  • Discuss the design and implementation of a national multi-stakeholder “Core Action Team” (CAT) to establish and improve use and uptake of RWE in decision-making
  • How CAT’s novel approach is improving collaboration between industry, regulators, HTA, payers, and researchers increasing RWE’s impact

Tarry Ahuja RWE Lead & Manager, Policy & Product Development Canadian Agency for Drugs & Technology in Health


Using pseudo-RWE to get clinical trials right from the outset

Christian Born Djurhuus VP, Head of Digital Transformation, Global Innovation Novo Nordisk


Panel: Generate RWE pre-approval to inform regulatory decisions and expand access

  • Better inform dossier submissions with new forms of evidence, such as comparative efficacy and cost to hospital, not traditionally part of RCT’s scope, with concurrent RWE studies.
  • Gain internal buy-in by working with regulators to inform evidence collection and use strategy.
  • Discuss next steps toward a new development paradigm with normalised RWE generation inclusion to supplement RCT data.
  • Understand implications of the Covid-19 pandemic; explore potential for RWE to ensure patients receive safe and effective treatments with minimal delay.

Chris Boone VP, Global Medical Epidemiology & Big Data Analysis Pfizer

Sam Hariry Head of Clinical Strategy & Operations Novartis

Giuseppe Rosano Member CVWP EMA

Carolyn Magill CEO Aetion


How the latest value-based agreements in Italy can inform good practice worldwide

Lara Pippo Head Market Access, Italy CSL Behring


Fireside chat: Define our purpose as value creators - and how to bring critical stakeholders with us with new innovative models

Iskra Reic Executive Vice President, Europe and Canada AstraZeneca


Thought leadership from Pfizer

Matthew Shaulis President, International Developed Markets, Inflammation & Immunology Pfizer

Day 5 (CET)


Case Study: How to initiate an effective turnaround plan that cascades through your business

  • Identify the obstacles you face when changing your core business model and how to overcome them
  • See the process Allergopharma used to identify the best of commercial pharma which it wanted to adopt – and the areas that were avoided

Philipp Maerz CEO Allergopharma


The impact of AI powered decision support tools for in-field roles

  • How customer expectations are evolving and what are the key principles for impactful engagements
  • Key steps for a successful adoption of AI tools by the sales force and how it covers the GAP between strategy and execution
  • What is the real impact of such initiatives

Ricardo Marques VP, Sales & Marketing TrueBlue


Closed-loop marketing: An integrated channel approach for consistent success

  • Ensure marketing, IT and external alignment to make sure capabilities are there to back-up marketing innovations
  • Make informed channel and content selection decisions by creating a backbone infrastructure that allows data flow across the company

Andreas Dach Digital & Multi-Channel Lead Eli Lilly


Real-world data as the trust catalyst for partnerships between pharma and healthcare systems

  • How RWD has played a critical role in establishing trusted partnerships
  • How to achieve better patient outcomes through RWE driven collaborations
  • Why RWD is the key to a performance based system, driven by real-time real-world insights

Michael Seewald VP, Global Evidence, Medical AstraZeneca


Virtual Research: What it Is & What It’s Doing in the Real-World Setting

David Thompson SVP, Real World and Late Phase Syneos Health


Real-world evidence: the disruptor enabling brand differentiation

  • Why RWE influences a brand strategy, not just a payer strategy
  • How RWE brings together the HCP community
  • Role of a cross-functional collaboration in RWE-generation to serve more patients

Victoria Williams Vice President, Respiratory Medicine Commercialisation Leader GSK


How patient data privacy and sovereignty is evolving

Richard Stephens Patient Advocate NCRI

Aida Ponce Senior Researcher ETUI


Empower commercial decision-making: Bring data from every interaction together

  • Define your digital investment strategy by creating a continuous feedback loop of engagement activity
  • Match the right data with the right internal usage to increase the efficiency of your analytics approach
  • Give reps and marketing strategists the advantage with a backbone infrastructure that links together separate systems spreading of insights and data throughout the business

Renaud Sermondade VP, Global Head of Insights and Analytics Sanofi

Ignacio Quiles Lara VP Oncology Commercial Director GSK

Paul Simms Chairman eyeforpharma by Reuters Events

Ricardo Marques VP, Sales & Marketing TrueBlue


How to create virtual trial participants

  • Understand the rationale and criteria for building virtual trial cohorts and compensate for lack of participant data
  • A journey through Ipsen’s process in building evidence with translational approaches, mixing RWE and clinical data, adding genomics, metabolomics and validating with the FDA
  • Use this aggregated information and high-quality algorithms to create predictions and best target identification

Stephane Orssaud R&D Biometry Innovation Director Ipsen


How to lower costs and speed up clinical studies with structured clinical data, electronic patient files and collaborative marketplaces

  • Learn current solutions to speeding up clinical trials and lowering costs in study set-up, execution and collaboration
  • Discover how pharma companies can find more hospitals and recruit patients more quickly with a marketplace for clinical studies
  • Understand how pharma companies can utilize FHIR based structured clinical data and electronic patient files to have live data in their studies

Stefan Wiesner CEO Healex


Interoperability – both technology and people – as the greatest win for patient care

  • Stop paralyzing your research – find ways to reduce the interoperability burden from the outset and get closer to the universal HER
  • Trust as the key currency for building an alliance for data sharing and efficient coalition between multiple institutions
  • How to work with regulators – understand the FDA/EMA mindset, build alliances and secure acceptance for your innovations

Joy Bhosai Chief of Digital Health & Strategy Duke University


Taking a strategic approach to early access

  • Assessing early access opportunities is increasingly a mainstream component of brand planning
  • The when, what and why of early access – key success factors
  • Ensuring synergy between early access and the commercial launch

Chris Easley Managing Director Huron


Panel: Reform or Revolution? Achieve affordable pricing for curative medicines

  • Learn how existing CAR-T and gene therapy agreements use RWE to demonstrate the long-term value of their treatments, whilst overcoming data quality deficiencies and methodology challenges
  • Discuss how to engage early with authorities to find flexible performance schemes that share risk fairly between both parties
  • Explore proposals on how to measure the long-term healthcare impact of preventive and curative treatments to satisfy HTA assessment

Alexander Natz Secretary General EUCOPE

Peter Bach Director Memorial Sloan Kettering Cancer Center


How value-based agreements are transitioning to a local level

Matt Portch Senior Vice President, Sales and Market Access Sunovio


Create an adaptive field force to meet customer expectations in the digital world

  • Find balance between virtual engagements and infield activity to ensure relationship building remains personal
  • Optimise rep engagement by ensuring the value of digital capabilities is clearly demonstrated, fostering greater transformation
  • Define the evolving role of the rep in the era of increased medical engagement, whilst increasing collaboration to create a seamless customer experience

Ignacio Quiles Lara VP Oncology Commercial Director GSK

Hélène Tixier VP, Head Global Digital & Multichannel strategy Sanofi Pasteur

Olivier Zitoun Life Sciences Global Sector Lead Capgemini

Nuno Rodrigues Digital & Multichannel Manager Roche


Leadership and the virtual field force

Rob Dickerson Former Head of Commercial Excellence Novartis


Pfizers new approach to patient engagement

Dara Richardson-Heron Chief Patient Officer Pfizer


Are We Relevant?

Christian Marcoux Senior Vice President, Global Communications Ipsen


Tuesday, 7th April - 11:00am–12:00pm

Create moments that matter to HCPs and patients: Does you brand plan currently deliver?
Hosted and facilitated by McCann

Current pressure to deliver more bang for your buck? In a shorter time-frame, and with fewer resources? You are not the only brand team feeling it.

In this increasingly pressured world, how do you:

  • Avoid the age-old pitfall of jumping straight from strategy to tactics without fully understanding the customer experience you need to create?
  • Drive the behaviour change needed for your brand to achieve prescription share ambition and revenue forecast, by creating meaningful moments that matter to your customers?

In this workshop, facilitators from our Consulting at McCann Health team will explore the importance of protecting time for customer immersion and highlight how disruptive creative thinking can act as a catalyst for changing customer behaviour.

Our facilitators will take you through an immersive session, providing you with tools and stimulus material to solve a genuine client challenge. You will not only be introduced to an approach that works, but you will also get the opportunity to put it into practice.

During the workshop our panel will share award-winning case studies to demonstrate the power of disruptive creative thinking.

Our case studies include real examples such as: a) disruptive thinking to increase rates of infant vaccination in several countries; and b) how QR codes are helping to tackle cervical cancer in China.

We believe in creating interactive learning experiences: this workshop is designed for those who want to participate in group discussion and are happy to dissect and challenge case studies with us.

We look forward to e-meeting you.

Wednesday, 8th April - 11:00am–12:00pm

Engage and collaborate to realize your true value to healthcare
Hosted and facilitated by Novasecta

Marketing, Medical Affairs, Market Access, and Insights and Analytics must proactively collaborate with internal and external stakeholders to continuously innovate and deliver value.

This workshop is built around our deep experience enabling teams from across the pharmaceutical industry to become more collaborative, increase their flexibility and deliver a clear view of how to realise their true value.

Join us for a roundtable discussion based on our client case studies that will challenge your thinking. We will help you to define and refine your ways of working to deliver greater value to your organisation and to patients, physicians and payers.

Sign up discuss how to:

  • Clarify internal and external stakeholder objectives and their expectations of you
  • Establish effective collaborations that optimise your and your partners value
  • Prioritise and efficiently execute decisions to have the greatest impact
  • Measure your impact and progress in stakeholder satisfaction

Wednesday, 8th April - 3:00pm–4:00pm

Profitable Growth in Recessionary Times
Hosted and facilitated by Capsys

The Covid-19 pandemic is an unprecedented public health and economic shock. We can confidently say that the "new normal", when it emerges, includes a deep recession and an acute capacity crisis in healthcare systems worldwide. How long they will last and how deep will be the effects, we don't yet know.

Recent history, especially the 2008 financial crisis, has shown that – even in highly uncertain times – companies can react with a longer-term view to defend share or even achieve continued growth. Together, we will look at pertinent case studies to understand what companies have done and identify choices and strategies that proved successful.

There will be an interactive assessment where you will gauge your company's readiness. How will your organizations stack up? To conclude, we will share recommendations on what YOU can do to improve your choices and defend growth.

In sum, participants will:

  • Explore case studies of companies that successfully defended or achieved growth during prior economic shocks;
  • Surface the core strategic choices that allow companies to succeed;
  • Assess their own company's readiness to respond;
  • Identify and prioritize key implications for their team, function and company.

Thursday, 9th April - 11:00am–12:00pm

Achieving sustainable transformation in cell & gene delivery to enable patient access, ensure quality, and optimise cost to deliver treatment?
Hosted and facilitated by Huron Consulting Group

Advanced technologies such as cell and gene therapies present new challenges to healthcare systems because of the differences in clinical development, manufacturing and delivery of these therapies and the fact they have evolved more quickly than the ecosystems that support them. Cell & Gene therapies (CGT) have the potential to upend traditional pharmaceutical manufacturing and supply chain models as well treatment delivery and both dimensions have a direct and sustainable impact on the cost & investment in infrastructure development which is a significant risk management issue that will confront major pharmaceutical & biotechnology organisations into 2020 and beyond.

Our workshop will discuss the challenges across the value chain that pharmaceutical and biotech companies face in commercialisation of cell and gene therapies and the attendees will gain a cross-functional view of the challenges in commercialising cell and gene therapies and discuss opportunities and solutions that work for the entire organisation.

The interactive event/workshop will use a case-study approach for a hypothetical asset and will aim to develop a go-to-market action plan. Participants will play the role of a developer/manufacturer’s cross-functional team and go through the following:

  • Review the value chain for the product, looking at the roles/experiences/motivations of the different stakeholders (patient, referring physician, treatment provider, payers and regulators)
  • Discuss the challenges and engagement opportunities associated with each stakeholder group
  • Brainstorm and cluster potential solutions through three lenses: regulatory (‘benefit/risk’), market access (funding and pricing) and commercialization (treatment delivery)
  • Pull these solutions together into a high-level, cross-functional plan

Santanu Das Managing Director Huron Consulting Group

Andrew Hobbs Managing Director Huron Consulting Group

Giles Thurston Principal Consultant Huron Consulting Group

Mark Perrott Head of Development Consulting Huron Consulting Group

Thursday, 9th April - 3:00pm–4:00pm

Drive meaningful online HCP engagement
Hosted and facilitated by EPG Health

Driving meaningful HCP online engagement

Deliver value aligned to educational objectives and digital behaviours

HCPs rate websites their number one source of information in clinical practice. However, it has never been harder for you (pharma) to connect with them online. We’ll explore data, real world insights and best practice guidance to improve HCP experience with your digital content and achieve results aligned to educational objectives.

Join medical affairs, marketing and digital peers in a tutorial with practical reflective activity and guidance aligned to your own HCP websites.

Learn how to:

  • Design personalised learning journeys aligned to key educational messages
  • Generate valuable content that’s optimised for HCP digital consumption preferences
  • Integrate multichannel nurture programmes to increase reach and sustain engagement
  • Use meaningful digital metrics to, understand, build and sustain engagement